DRUGS & SUPPLEMENTS

Imovax Pneumo 23

Name: Imovax Pneumo 23 drug & pharmaceuticals. Available Forms, Doses, Prices
Creator: sdrugs.com
Published: 2021-11-11T10:10:10+00:00

What do you feel about the cost of the medicine? Is it expensive?

Imovax Pneumo 23 uses

Indications and usage
Dosage and administration
Dosage forms and strengths
Contraindications
Warnings and precautions
Adverse reactions
Drug interactions
Use in specific populations
Description
Clinical pharmacology
Clinical studies
References
How supplied/storage and handling
Patient counseling information
Imovax Pneumo 23 reviews

1 INDICATIONS AND USAGE

Imovax Pneumo 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine. (1.1)

Imovax Pneumo 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. (1.1, 14.1)

1.1 Indications and Use

PNEUMOVAX^® 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). Imovax Pneumo 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

1.2 Limitations of Use

Imovax Pneumo 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

2 DOSAGE AND ADMINISTRATION

For intramuscular or subcutaneous injection only.

Single 0.5-mL dose of Imovax Pneumo 23 administered intramuscularly or subcutaneously only.

2.1 Preparation

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If either of these two conditions exists, the vaccine should not be administered.
Do not mix Imovax Pneumo 23 with other vaccines in the same syringe or vial.
Use a separate sterile syringe and needle for each individual patient to prevent transmission of infectious agents from one person to another.
Single-Dose and Multidose Vials
Withdraw 0.5 mL from the vial using a sterile needle and syringe free of preservatives, antiseptics, and detergents.
Single-Dose, Prefilled Syringe
The package does not contain a needle. Attach a sterile needle to the prefilled syringe by twisting in a clockwise direction until the needle fits securely on the syringe.

2.2 Administration

Administer Imovax Pneumo 23 intramuscularly or subcutaneously into the deltoid muscle or lateral mid-thigh. Do not inject intravascularly or intradermally.

Single-Dose and Multidose Vials

Administer a single 0.5-mL dose of Imovax Pneumo 23 using a sterile needle and syringe.

Single-Dose, Prefilled Syringe

Administer the entire contents of the single-dose, prefilled syringe per standard protocol using a sterile needle.

2.3 Revaccination

The Advisory Committee on Immunization Practices (ACIP) has recommendations for revaccination against pneumococcal disease for persons at high risk who were previously vaccinated with Imovax Pneumo 23. Routine revaccination of immunocompetent persons previously vaccinated with a 23-valent vaccine, is not recommended.{1,2}

3 DOSAGE FORMS AND STRENGTHS

Imovax Pneumo 23 is a clear, sterile solution supplied in a (0.5-mL dose) single-dose vial, a 5-dose vial, and a single-dose, prefilled syringe.

Clear, sterile solution supplied in a (0.5-mL dose) single-dose vial, a multidose (5-dose) vial, and a single-dose, prefilled syringe. (3)

4 CONTRAINDICATIONS

Severe allergic reaction to any component of Imovax Pneumo 23. (4.1)

4.1 Hypersensitivity

Do not administer Imovax Pneumo 23 to individuals with a history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine.

5 WARNINGS AND PRECAUTIONS

Use caution and appropriate care for individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

5.1 Persons with Moderate or Severe Acute Illness

Defer vaccination with Imovax Pneumo 23 in persons with moderate or severe acute illness.

5.2 Persons with Severely Compromised Cardiovascular or Pulmonary Function

Caution and appropriate care should be exercised in administering Imovax Pneumo 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

5.3 Use of Antibiotic Prophylaxis

This vaccine does not replace the need for penicillin prophylaxis against pneumococcal infection. In patients who require penicillin (or other antibiotic) prophylaxis against pneumococcal infection, such prophylaxis should not be discontinued after vaccination with Imovax Pneumo 23.

5.4 Persons with Altered Immunocompetence

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to Imovax Pneumo 23.

5.5 Persons with Chronic Cerebrospinal Fluid Leakage

Imovax Pneumo 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

6 ADVERSE REACTIONS

The most common adverse reactions, reported in >10% of subjects vaccinated with Imovax Pneumo 23 in clinical trials were: injection-site pain/soreness/tenderness, injection-site swelling/induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia/fatigue (13.2%), and myalgia (11.9%).

The most common adverse reactions, reported in >10% of subjects vaccinated with Imovax Pneumo 23 in clinical trials, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

In a randomized, double-blind, placebo-controlled crossover clinical trial, subjects were enrolled in four different cohorts defined by age (50-64 years of age and ≥65 years of age) and vaccination status (no pneumococcal vaccination or receipt of a pneumococcal polysaccharide vaccine 3-5 years prior to the study). Subjects in each cohort were randomized to receive intramuscular injections of Imovax Pneumo 23 followed by placebo (saline containing 0.25% phenol), or placebo followed by Imovax Pneumo 23, at 30-day (±7 days) intervals. The safety of an initial vaccination (first dose) was compared to revaccination (second dose) with Imovax Pneumo 23 for 14 days following each vaccination.

All 1008 subjects (average age, 67 years; 49% male and 51% female; 91% Caucasian, 4.7% African-American, 3.5% Hispanic, and 0.8% Other) received placebo injections.

Initial vaccination was evaluated in a total of 444 subjects (average age 65 years; 32% male and 68% female; 93% Caucasian, 3.2% African-American, 3.4% Hispanic, and 1.1% Other).

Revaccination was evaluated in 564 subjects (average age 69 years; 53% male and 47% female; 90% Caucasian, 3.5% Hispanic, 6.0% African-American, and 0.5% Other).

Serious Adverse Experiences

In this study, 10 subjects had serious adverse experiences within 14 days of vaccination: 6 who received Imovax Pneumo 23 and 4 who received placebo. Serious adverse experiences within 14 days after Imovax Pneumo 23 included angina pectoris, heart failure, chest pain, ulcerative colitis, depression, and headache/tremor/stiffness/sweating. Serious adverse experiences within 14 days after placebo included myocardial infarction complicated with heart failure, alcohol intoxication, angina pectoris, and edema/urinary retention/heart failure/diabetes.

Five subjects reported serious adverse experiences that occurred outside the 14-day follow-up window: 3 who received Imovax Pneumo 23 and 2 who received placebo. Serious adverse experiences after Imovax Pneumo 23 included cerebrovascular accident, lumbar radiculopathy, and pancreatitis/myocardial infarction resulting in death. Serious adverse experiences after placebo included heart failure and motor vehicle accident resulting in death.

Solicited and Unsolicited Reactions

Table 1 presents the adverse event rates for all solicited and unsolicited reactions reported in ≥1% in any group in this study, without regard to causality.

The most common local adverse reactions reported at the injection site after initial vaccination with Imovax Pneumo 23 were pain/tenderness/soreness (60.0%), swelling/induration (20.3%), and erythema (16.4%). The most common systemic adverse experiences were headache (17.6%), asthenia/fatigue (13.2%), and myalgia (11.9%).

The most common local adverse reactions reported at the injection site after revaccination with Imovax Pneumo 23 were pain/soreness/tenderness (77.2%), swelling (39.8%), and erythema (34.5%). The most common systemic adverse reactions with revaccination were headache (18.1%), asthenia/fatigue (17.9%), and myalgia (17.3%). All of these adverse reactions were reported at a rate lower than 10% after receiving a placebo injection.

	Imovax Pneumo 23 Initial Vaccination	Imovax Pneumo 23 RevaccinationSubjects receiving their second dose of pneumococcal polysaccharide vaccine as Imovax Pneumo 23 approximately 3-5 years after their first dose.	Placebo InjectionSubjects receiving placebo injection from this study combined over periods.
	N=444	N=564	N=1008
Number Followed for Safety	438	548	984The number of subjects receiving placebo followed for injection-site complaints. The corresponding number of subjects followed for systemic complaints was 981.
	AE Rate	AE Rate	AE Rate
Injection-Site Complaints
Solicited Events
Pain/Soreness/Tenderness	60.0%	77.2%	7.7%
Swelling/Induration	20.3%	39.8%	2.8%
Erythema	16.4%	34.5%	3.3%
Unsolicited Events
Ecchymosis	0%	1.1%	0.3%
Pruritus	0.2%	1.6%	0.0%
Systemic Complaints
Solicited Events
Asthenia/Fatigue	13.2%	17.9%	6.7%
Chills	2.7%	7.8%	1.8%
Myalgia	11.9%	17.3%	3.3%
Headache	17.6%	18.1%	8.9%
Unsolicited Events
FeverFever events include subjects who felt feverish in addition to subjects with elevated temperature.	1.4%	2.0%	0.7%
Diarrhea	1.1%	0.7%	0.5%
Dyspepsia	1.1%	1.1%	0.9%
Nausea	1.8%	1.8%	0.9%
Back Pain	0.9%	0.9%	1.0%
Neck Pain	0.7%	1.5%	0.2%
Upper Respiratory Infection	1.8%	2.6%	1.8%
Pharyngitis	1.1%	0.4%	1.3%

In this clinical study an increased rate of local reactions was observed with revaccination at 3-5 years following initial vaccination.

For subjects aged 65 years or older, injection-site adverse reaction rate was higher following revaccination (79.3%) than following initial vaccination (52.9%). The proportion of subjects reporting injection site discomfort that interfered with or prevented usual activity or injection site induration ≥4 inches was higher following revaccination (30.6%) than following initial vaccination (10.4%). Injection site reactions typically resolved by 5 days following vaccination.

For subjects aged 50-64 years, the injection-site adverse reaction rate for revaccinees and initial vaccinees was similar (79.6% and 72.8% respectively).

The rate of systemic adverse reactions was similar among both initial vaccinees and revaccinees within each age group. The rate of vaccine-related systemic adverse reactions was higher following revaccination (33.1%) than following initial vaccination (21.7%) in subjects 65 years of age or older, and was similar following revaccination (37.5%) and initial vaccination (35.5%) in subjects 50-64 years of age. The most common systemic adverse reactions reported after Imovax Pneumo 23 were as follows: asthenia/fatigue, myalgia and headache.

Regardless of age, the observed increase in post vaccination use of analgesics (≤13% in the revaccinees and ≤4% in the initial vaccinees) returned to baseline by day 5.

6.2 Post-Marketing Experience

The following list of adverse reactions includes those identified during post approval use of Imovax Pneumo 23. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or their causal relationship to product exposure.

General disorders and administration site conditions

Cellulitis

Malaise

Fever (>102°F)

Warmth at the injection site

Decreased limb mobility

Peripheral edema in the injected extremity

Digestive System

Nausea

Vomiting

Hematologic/Lymphatic

Lymphadenitis

Lymphadenopathy

Thrombocytopenia in patients with stabilized idiopathic thrombocytopenic purpura{3}

Hemolytic anemia in patients who have had other hematologic disorders

Leukocytosis

Hypersensitivity reactions including

Anaphylactoid reactions

Serum Sickness

Angioneurotic edema

Musculoskeletal System

Arthralgia

Arthritis

Nervous System

Paresthesia

Radiculoneuropathy

Guillain-Barré syndrome

Febrile convulsion

Skin

Rash

Urticaria

Cellulitis-like reactions

Erythema multiforme

Investigations

Increased serum C-reactive protein

7 DRUG INTERACTIONS

In a randomized clinical study, a reduced immune response to ZOSTAVAX® as measured by gpELISA was observed in individuals who received concurrent administration of Imovax Pneumo 23 and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks.

7.1 Concomitant Administration with Other Vaccines

Limited safety and immunogenicity data from clinical trials are available on the concurrent administration of Imovax Pneumo 23 and vaccines other than ZOSTAVAX.

8 USE IN SPECIFIC POPULATIONS

Pregnancy: No human or animal data are available. Use only if clearly needed.

Pediatrics: Imovax Pneumo 23 is not approved for use in children younger than 2 years of age because children in this age group do not develop an effective immune response to capsular types contained in the polysaccharide vaccine. (8.4)

Geriatrics: For subjects aged 65 years or older in a clinical study systemic adverse reactions, determined by the investigator to be vaccine-related, were higher following revaccination (33.1%) than following initial vaccination (21.7%). Routine revaccination of immunocompetent persons previously vaccinated with a 23-valent vaccine, is not recommended.{1} (8.5)

Immunocompromised Individuals: Response to vaccination may be diminished. (5.4, 8.6)

8.1 Pregnancy

Pregnancy Category C: Animal reproduction studies have not been conducted with Imovax Pneumo 23. It is also not known whether Imovax Pneumo 23 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Imovax Pneumo 23 should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Imovax Pneumo 23 is administered to a nursing woman.

8.4 Pediatric Use

Imovax Pneumo 23 is not approved for use in children less than 2 years of age. Children in this age group do not develop an effective immune response to the capsular types contained in this polysaccharide vaccine.

The ACIP has recommendations for use of Imovax Pneumo 23 in children 2 years of age or older, who have previously received pneumococcal vaccines, and who are at increased risk for pneumococcal disease.{2}

8.5 Geriatric Use

In one clinical trial of Imovax Pneumo 23, conducted post-licensure, a total of 629 subjects who were aged ≥65 years and 201 subjects who were aged ≥75 years were enrolled.

In this trial, the safety of Imovax Pneumo 23 in adults 65 years of age and older was compared to the safety of Imovax Pneumo 23 in adults 50 to 64 years of age (N=379). The subjects in this study had underlying chronic illness but were in stable condition; at least 1 medical condition at enrollment was reported by 86.3% of subjects who were 50 to 64 years old, and by 96.7% of subjects who were 65 to 91 years old. The rate of vaccine-related systemic adverse experiences was higher following revaccination (33.1%) than following primary vaccination (21.7%) in subjects ≥65 years of age, and was similar following revaccination (37.5%) and primary vaccination (35.5%) in subjects 50 to 64 years of age.

Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

Post-marketing reports have been received in which some elderly individuals had severe adverse experiences and a complicated clinical course following vaccination. Some individuals with underlying medical conditions of varying severity experienced local reactions and fever associated with clinical deterioration requiring hospital care.

8.6 Immunocompromised Individuals

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to Imovax Pneumo 23.

11 DESCRIPTION

Imovax Pneumo 23 (Pneumococcal Vaccine Polyvalent) is a sterile, liquid vaccine consisting of a mixture of purified capsular polysaccharides from Streptococcus pneumoniae types (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Imovax Pneumo 23 is a clear, colorless solution. Each 0.5-mL dose of vaccine contains 25 micrograms of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative. The vaccine is used directly as supplied. No dilution or reconstitution is necessary.

The vial stoppers, syringe plunger stopper and syringe tip cap are not made with natural rubber latex.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Imovax Pneumo 23 induces type-specific antibodies that enhance opsonization, phagocytosis, and killing of pneumococci by leukocytes and other phagocytic cells. The levels of antibodies that correlate with protection against pneumococcal disease have not been clearly defined.

14 CLINICAL STUDIES

14.1 Effectiveness

The protective efficacy of pneumococcal vaccines containing six or twelve (types 1, 2, 3, 4, 6A, 8, 9N, 12F, 25, 7F, 18C, and 46) capsular polysaccharides was investigated in two controlled studies in South Africa in male novice gold miners ranging in age from 16 to 58 years, in whom there was a high attack rate for pneumococcal pneumonia and bacteremia.{4} In both studies, participants in the control groups received either meningococcal polysaccharide serogroup A vaccine or saline placebo. In both studies, attack rates for vaccine type pneumococcal pneumonia were observed for the period from 2 weeks through about 1 year after vaccination. Protective efficacy was 76% and 92%, respectively, for the 6- and 12-valent vaccines, for the capsular types represented.

Three similar studies in South African young adult male novice gold miners were carried out by Dr. R. Austrian and associates{5} using similar pneumococcal vaccines prepared for the National Institute of Allergy and Infectious Diseases, with pneumococcal vaccines containing a 6-valent formulation (types 1, 3, 4, 7, 8, and 12) or a 13-valent formulation (types 1, 2, 3, 4, 6, 7, 8, 9, 12, 14, 18, 19, and 25) capsular polysaccharides. The reduction in pneumococcal pneumonia caused by the capsular types contained in the vaccines was 79%. Reduction in type-specific pneumococcal bacteremia was 82%.

A prospective study in France found a Imovax Pneumo 23 containing fourteen (types 1, 2, 3, 4, 6A, 7F, 8, 9N, 12F, 14, 18C, 19F, 23F, and 25) capsular polysaccharides to be 77% (95%CI: 51% to 89%) effective in reducing the incidence of pneumonia among male and female nursing home residents with a mean age of 74 (standard deviation of 4 years).{6}

In a study using a Imovax Pneumo 23 containing eight (types 1, 3, 6, 7, 14, 18, 19, and 23) capsular polysaccharides, vaccinated children and young adults aged 2 to 25 years who had sickle cell disease, congenital asplenia, or undergone a splenectomy experienced significantly less bacteremic pneumococcal disease than patients who were not vaccinated.{7}

In the United States, one post-licensure randomized controlled trial, in the elderly or patients with chronic medical conditions who received a 14-valent pneumococcal polysaccharide vaccine (types 1, 2, 3, 4, 6A, 8, 9N, 12F, 14, 19F, 23F, 25, 7F, and 18C), did not support the efficacy of the vaccine for nonbacteremic pneumonia.{8}

A retrospective cohort analysis study based on the U.S. Centers for Disease Control and Prevention (CDC) pneumococcal surveillance system, showed 57% (95%CI: 45% to 66%) overall protective effectiveness against invasive infections caused by serotypes included in Imovax Pneumo 23 in persons ≥6 years of age, 65 to 84% effectiveness among specific patient groups (e.g., persons with diabetes mellitus, coronary vascular disease, congestive heart failure, chronic pulmonary disease, and anatomic asplenia) and 75% (95%CI: 57% to 85%) effectiveness in immunocompetent persons aged ≥65 years of age. Vaccine effectiveness could not be confirmed for certain groups of immunocompromised patients.{9}

14.2 Immunogenicity

The levels of antibodies that correlate with protection against pneumococcal disease have not been clearly defined.

Antibody responses to most pneumococcal capsular types are generally low or inconsistent in children less than 2 years of age.

14.3 Concomitant Administration with Other Vaccines

In a double-blind, controlled clinical trial, 473 adults, 60 years of age or older, were randomized to receive ZOSTAVAX and Imovax Pneumo 23 concomitantly (N=237), or Imovax Pneumo 23 alone followed 4 weeks later by ZOSTAVAX alone (N=236). At four weeks postvaccination, the varicella-zoster virus (VZV) antibody levels following concomitant use were significantly lower than the VZV antibody levels following nonconcomitant administration (GMTs of 338 vs. 484 gpELISA units/mL, respectively; GMT ratio = 0.70 (95% CI: [0.61, 0.80]).

Limited safety and immunogenicity data from clinical trials are available on the concurrent administration of Imovax Pneumo 23 and vaccines other than ZOSTAVAX.

15 REFERENCES

Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 46(No. RR-8): 1-25, 1997. Available from: http://www.cdc.gov/mmwr/PDF/rr/rr4608.pdf
Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine, MMWR 59(RR11): 1-18, 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm?s_cid=rr5911a1_e
Kelton, J.G.: Vaccination-associated relapse of immune thrombocytopenia, JAMA. 245(4): 369-371, 1981.
Smit, P.; Oberholzer, D.; Hayden-Smith, S.; Koornhof, H.J.; Hilleman, M.R.: Protective efficacy of pneumococcal polysaccharide vaccines, JAMA. 238: 2613-2616, 1977.
Austrian, R.; Douglas, R.M.; Schiffman, G.; Coetzee, A.M.; Koornhof, H.J.; Hayden-Smith, S.; Reid, R.D.W.: Prevention of pneumococcal pneumonia by vaccination, Trans. Assoc. Am. Physicians. 89: 184-194, 1976.
Gaillat, J.; Zmirou, D.; Mallaret, M.R.: Essai clinique du vaccin antipneuomococcique chez des personnes agees vivant en institution, Rev. Epidemiol. Sante Publique. 33: 437-44, 1985.
Ammann, A.J.; Addiego, J.; Wara, D.W.; Lubin, B.; Smith, W.B.; Mentzer, W.C.: Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy, N. Engl. J. Med. 297: 897-900, 1977.
Simberkoff, M.S.; Cross, A.P.; Al-Ibrahim, M.: Efficacy of Imovax Pneumo 23 in high risk patients: results of a Veterans Administration cooperative study, N. Engl. J. Med. 315: 1318-27, 1986.
Butler, J.C.; Breiman, R.F.; Campbell, J.F.; Lipman, H.B.; Broome, C.V.; Facklam, R.R.: Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations, JAMA. 270: 1826-31, 1993.
Vaccine Adverse Event Reporting System - United States, MMWR. 39(41): 730-33, October 19, 1990.

16 HOW SUPPLIED/STORAGE AND HANDLING

Imovax Pneumo 23 is supplied as follows:

NDC 0006-4739-00 - one 5-dose vial, color coded with a purple cap and stripe on the vial labels and cartons.

NDC 0006-4943-00 - a box of 10 single-dose vials, color coded with a purple cap and stripe on the vial labels and cartons.

NDC 0006-4837-03 - a box of 10 single-dose, pre-filled Luer-Lok syringes with tip caps, color coded with a violet plunger rod and purple stripe on the syringe labels and cartons.

NDC 0006-4837-02 - a box of 1 single-dose, pre-filled Luer-Lok syringe with tip cap, color coded with a violet plunger rod and purple stripe on the syringe label and carton.

Storage and Handling

Store at 2-8°C (36-46°F).
All vaccine must be discarded after the expiration date.

The vial stoppers, syringe plunger stopper and syringe tip cap are not made with natural rubber latex.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform the patient, parent or guardian of the benefits and risks associated with vaccination.
Tell the patient, parent or guardian that vaccination with Imovax Pneumo 23 may not offer 100% protection from pneumococcal infection.
Provide the patient, parent or guardian with the vaccine information statements required by the National Childhood Vaccine Injury Act of 1986, with each immunization.
Instruct the patient, parent or guardian to report any serious adverse reactions to their health care provider who in turn should report such events to the vaccine manufacturer or the U.S. Department of Health and Human Services through the Vaccine Adverse Event Reporting System (VAERS), 1-800-822-7967, or report online at www.vaers.hhs.gov. {10}

Manuf. and Dist. by: Merck Sharp & Dohme Corp., a subsidiary of

MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

For patent information: www.merck.com/product/patent/home.html

The trademarks depicted herein are owned by their respective companies.

uspi-v110-i-1505r041

Printed in USA

Patient Information about

PNEUMOVAX^® 23 (pronounced "noo-mo-vax 23")

Generic Name: Imovax Pneumo 23 polyvalent

Read this leaflet before you or your child gets the vaccine called Imovax Pneumo 23. If you have any questions about the vaccine after you read this, you should ask your health care provider. This is a summary only. It does not take the place of talking to your doctor, nurse or other health care provider about the vaccine. Only your health care provider can decide if Imovax Pneumo 23 is right for you or your child.

What is Imovax Pneumo 23?

Imovax Pneumo 23 is a vaccine that is given as a shot. It helps protect you from infection by certain germs or bacteria which are called pneumococcus (pronounced "noo-mo-ca-cus"). Imovax Pneumo 23 is for people 50 years of age and older. It is also for people who are 2 years of age and older if they have certain medical conditions that put them at increased risk for infection.

Illnesses or health problems may allow these germs to spread into the blood, lungs, or brain where they can cause serious diseases such as:

An infection in the blood
A lung infection (pneumonia) that can also come with an infection in the blood
An infection of the coverings of the brain and spinal cord (meningitis).

Imovax Pneumo 23 may not protect everyone who gets it. It will not protect against diseases that are caused by bacteria types that are not in the vaccine.

Who should not get Imovax Pneumo 23?

You should not get this vaccine if you (or your child):

are allergic to any of its ingredients
had an allergic reaction to Imovax Pneumo 23 in the past
are less than 2 years old.

What should I tell my health care provider before getting Imovax Pneumo 23?

Tell your health care provider if you (or your child):

are allergic to Imovax Pneumo 23
have heart or lung problems
have a fever
have immune problems or are receiving radiation treatment for chemotherapy
are pregnant or breast-feeding

How is Imovax Pneumo 23 given?

Most often, just one shot is given.

If you or your child is in a high-risk group for pneumococcal infection, then your health care provider will decide if it would be helpful to give a second shot of Imovax Pneumo 23 at a later time.

Can Imovax Pneumo 23 be given with other vaccines?

Talk to your health care provider if you plan to get ZOSTAVAX at the same time as Imovax Pneumo 23 because it may be better to get these vaccines at least 4 weeks apart.

Talk to your health care provider if you plan to get Imovax Pneumo 23 at the same time as other vaccines.

What are the possible side effects of Imovax Pneumo 23?

The most common side effects are:

pain, warmth, soreness, redness, swelling, and hardening at the injection site
headache
weakness, feeling tired
muscle pain

Tell your health care provider or get emergency help right away if you get any of the following problems after vaccination because these may be signs of an allergic reaction or other serious conditions:

difficulty breathing
wheezing
rash
hives

Side effects at the site where you get the shot may be more common and may feel worse after a second shot than after the first shot.

Tell your health care provider if you or your child has a side effect that bothers you or that does not go away.

For a more complete list of side effects, ask your health care provider.

You may also report any side effect to your or your child's health care provider, or directly to the Vaccine Adverse Event Reporting System (VAERS). You may call the VAERS number 1-800-822-7967 at no charge, or report online to www.vaers.hhs.gov.

What are the ingredients of Imovax Pneumo 23?

Active Ingredients:	Bacterial sugars from 23 pneumococcal types: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
Inactive Ingredients:	Phenol (a preservative)

What else should I know about Imovax Pneumo 23?

Some adults and children have problems with leakage of spinal fluid after the skull is cracked or injured or after medical operations and this may increase their risk for pneumococcal infection. Imovax Pneumo 23 may not be able to prevent all of these infections.

The vial stoppers, syringe plunger stopper and syringe tip cap for Imovax Pneumo 23 are not made with natural rubber latex.

This leaflet is a summary of information about Imovax Pneumo 23. If you would like more information, talk to your health care provider. You can also call the Merck National Service Center at 1-800-622-4477.

Manuf. and Dist. by: Merck Sharp & Dohme Corp., a subsidiary of

MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

For patent information: www.merck.com/product/patent/home.html

Revised: 05/2015

usppi-v110-i-1505r039

Printed in USA

Rx Only

Imovax Pneumo 23 pharmaceutical active ingredients containing related brand and generic drugs:

Pneumococcal Vaccine

Imovax Pneumo 23 available forms, composition, doses:

Injectable; Injection; Pneumococcal Vaccine

Imovax Pneumo 23 destination | category:

Human:
Vaccines, antisera and immunologicals

Imovax Pneumo 23 Anatomical Therapeutic Chemical codes:

J07AL - Pneumococcal vaccines

Imovax Pneumo 23 pharmaceutical companies:

Frequently asked Questions

Can i drive or operate heavy machine after consuming Imovax Pneumo 23?

Depending on the reaction of the Imovax Pneumo 23 after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Imovax Pneumo 23 not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Imovax Pneumo 23 addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Imovax Pneumo 23, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Imovax Pneumo 23 consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.